Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 358

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 358
---
 in 2025. •Total payments for health care, long -termcare and hospice care for people with Alzheimer’s disease and other dementias are projected to increase to nearly $1 trillion in 2050. The total lifetime cost of care for someone with dementia is estimated at $371,621. The figure below, adapted from the Alzheimer’s Association Report presents percentage changes in selected causes of death between 2000 and 2022 (all ages). While the proportion of deaths from heart disease, stroke, breast and prostate cancer, and HIV decreased, the proportion of deaths from AD in the US increased by over 140%. Percentage Changes in Selected Causes of Death (All Ages) in the US between 2000 and 2022 202 Over the past 20 years, several investigational drugs for AD failed in clinical development. These drugs were intended to affect different aspects of AD pathology. A fundamental challenge of AD is that at the point at which physicians can render a definitive diagnosis, the patient has already suffered massive neuronal loss leading to overt cognitive dysfunction. Thus, clinical trials that are conducted in patients with advanced disease at the time of their enrollment may be targeting subjects too late in the disease progression for any meaningful impact on disease by the drug being tested. However, recently a number of high -profilepositive study results, have brought hope for treatment options for AD, including the TRAILBLAZER -ALZ2 Phase 3 study done by Eli Lilly and Company (NYSE: LLY) in May 2023 (( https://investor.lilly.com/news -releases /news -release-details /lillysdonanemab -significantly-slowed-cognitive-and-functional) and the Phase 3 randomized study data for lecanemab done by Eiasi and Biogen in November 2022 ( https://investors.biogen.com/news -releases /news -release-details /fda -grants-traditionalapproval - leqembir -lecanemab-irmb). On July 6, 2023, the FDA granted full approval for lecanemab, which was shown to moderately slow cognitive and functional decline in early -stagecases of the disease. On July 2024, Eli Lilly announced that the FDA has approved its anti -amyloidbeta monoclonal antibody Kisunla (donanemab) for the treatment of patients with MCI and mild AD ( https://investor.lilly.com/news -releases /news -release-details